BioSpace News Archive

BillionToOne (BTO) is pleased to announce a global collaboration with Janssen Research & Development, LLC, a Johnson & Johnson company (Johnson & Johnson), in the AZALEA Phase 3 clinical trial of nipocalimab in pregnancies at risk for severe hemolytic disease of the fetus and newborn (HDFN).

Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) today announced an engagement with The Sage Group (www.sagehealthcare.com) to assist the company in exploring strategic partnerships, co-development and licensing agreements for tecarfarin.

Psycheceutical Bioscience, Inc. is thrilled to announce the appointment of Dr. Neilank K. Jha as its new Executive Chairman and Chief Executive Officer.

Protagonist Therapeutics, Inc. (“Protagonist” or the “Company”) announced details from five abstracts at the American Society of Hematology 2023 Annual Meeting, including an oral presentation with two-year follow up data from the Phase 2 REVIVE study with rusfertide, a mimetic of the natural hormone hepcidin with potential therapeutic value in the treatment of polycythemia vera (PV) and other disease indications.

December 12, 2023) - Britannia Life Sciences Inc. (CSE: BLAB) (FSE: L020) (“Britannia” or the “Company”) is pleased to announce the appointment of Mark Bowes-Cavanagh as Chief Executive Officer

BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that the United States Patent and Trademark Office has issued a notice of allowance for a patent application related to the Company’s metabolic ThermoStem® program.

Cassava Sciences, Inc. announced a pro rata dividend distribution of warrants to holders of the Company’s common stock as of December 22, 2023.

CathVision, a medical technology company developing innovative electrophysiology solutions designed to enhance clinical decision making in the EP lab, announced the launch of ECGenius 3.1, an advanced version of the ECGenius™ System software.

ImmunoScape, a biotechnology company focused on next-generation immunotherapies, announced the appointment of John Tsang, Ph.D. to its Scientific Advisory Board.

Zeteo Tech, Inc. announced that it has been awarded a Phase III Small Business Innovation Research contract for $1.87M with a potential value of up to $5.86 million from the U.S. Department of Homeland Security.